144 related articles for article (PubMed ID: 15133631)
21. Cytotoxic T lymphocyte epitopes of HIV-1 Nef: Generation of multiple definitive major histocompatibility complex class I ligands by proteasomes.
Lucchiari-Hartz M; van Endert PM; Lauvau G; Maier R; Meyerhans A; Mann D; Eichmann K; Niedermann G
J Exp Med; 2000 Jan; 191(2):239-52. PubMed ID: 10637269
[TBL] [Abstract][Full Text] [Related]
22. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
[TBL] [Abstract][Full Text] [Related]
23. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
Denkberg G; Klechevsky E; Reiter Y
J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
[TBL] [Abstract][Full Text] [Related]
24. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice.
Bullock TN; Colella TA; Engelhard VH
J Immunol; 2000 Mar; 164(5):2354-61. PubMed ID: 10679070
[TBL] [Abstract][Full Text] [Related]
25. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
26. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
[TBL] [Abstract][Full Text] [Related]
27. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
[TBL] [Abstract][Full Text] [Related]
28. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
Yang S; Linette GP; Longerich S; Haluska FG
J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
[TBL] [Abstract][Full Text] [Related]
29. Solid-phase epitope recovery: a high throughput method for antigen identification and epitope optimization.
Lawendowski CA; Giurleo GM; Huang YY; Franklin GJ; Kaplan JM; Roberts BL; Nicolette CA
J Immunol; 2002 Sep; 169(5):2414-21. PubMed ID: 12193709
[TBL] [Abstract][Full Text] [Related]
30. Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones.
Sensi M; Pellegatta S; Vegetti C; Nicolini G; Parmiani G; Anichini A
Tissue Antigens; 2002 Apr; 59(4):273-9. PubMed ID: 12135425
[TBL] [Abstract][Full Text] [Related]
31. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope.
Theobald M; Ruppert T; Kuckelkorn U; Hernandez J; Häussler A; Ferreira EA; Liewer U; Biggs J; Levine AJ; Huber C; Koszinowski UH; Kloetzel PM; Sherman LA
J Exp Med; 1998 Sep; 188(6):1017-28. PubMed ID: 9743520
[TBL] [Abstract][Full Text] [Related]
32. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
33. Limited diversity of peptides related to an alloreactive T cell epitope in the HLA-B27-bound peptide repertoire results from restrictions at multiple steps along the processing-loading pathway.
Paradela A; Alvarez I; García-Peydró M; Sesma L; Ramos M; Vázquez J; López De Castro JA
J Immunol; 2000 Jan; 164(1):329-37. PubMed ID: 10605027
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.
Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Teates D; Neese P; Grosh WW; Petroni G; Engelhard VH; Slingluff CL
Int J Cancer; 2001 Jun; 92(5):703-11. PubMed ID: 11340576
[TBL] [Abstract][Full Text] [Related]
35. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
[TBL] [Abstract][Full Text] [Related]
36. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
[TBL] [Abstract][Full Text] [Related]
37. Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones.
Kirkin AF; thor Straten P; Hansen MR; Barfoed A; Dzhandzhugazyan KN; Zeuthen J
Cancer Immunol Immunother; 1999 Aug; 48(5):239-46. PubMed ID: 10478640
[TBL] [Abstract][Full Text] [Related]
38. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
[TBL] [Abstract][Full Text] [Related]
39. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G
J Immunol; 1999 Feb; 162(3):1739-48. PubMed ID: 9973437
[TBL] [Abstract][Full Text] [Related]
40. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins.
Kang X; Robbins PF; Fitzgerald EB; Wang R; Rosenberg SA; Kawakami Y
Cancer Res; 1997 Jan; 57(2):202-5. PubMed ID: 9000554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]